Support the news

Cambridge Biotech Company Claims Breakthrough On New Class Of 'Gene-Silencing' Drugs04:37

This article is more than 2 years old.

Stock in the Cambridge pharmaceutical company, Alnylam, is soaring due to expectations it may have successfully tested a so-called "RNAI" drug that could treat a rare malfunction of the nervous system. Luke Timmerman, who writes the bio-tech newsletter "The Timmerman Report," joined Morning Edition.

This segment aired on September 22, 2017.

Bob Oakes Twitter Host, Morning Edition
Bob Oakes has been WBUR's Morning Edition anchor since 1992.


+Join the discussion

Support the news